#United States #New York #Securities Laws #Faruqi & Faruqi #Hims & Hers

Investigation Initiated for Hims & Hers Health Shareholders

On July 3, 2025, Faruqi & Faruqi, LLP, a prominent national securities law firm, officially announced their investigation into potential claims involving Hims & Hers Health, Inc. This follows recent disclosures regarding the company's deceptive practices that have adversely affected investors.

According to information disclosed, Faruqi & Faruqi urges anyone who purchased or acquired Hims securities between April 29, 2025, and June 22, 2025, to reach out for a consultation regarding their legal rights. Notably, the impending deadline of August 25, 2025, will determine who may take on the role of lead plaintiff in a federal class action lawsuit against the company.

In detail, the complaint alleges that Hims & Hers Health misled its investors by making inaccurate or misleading claims about their operations and business practices. A report indicates that Hims engaged in “deceptive promotion and selling of illegitimate, knockoff versions of Wegovy®,” potentially jeopardizing patient safety. Furthermore, it highlights that the company's communication regarding its business outlook was materially misleading and unsupported by factual accuracy.

The situation escalated when Novo Nordisk, a significant collaborator with Hims, publicly terminated its partnership on June 23, 2025. The announcement cited Hims' failure to comply with legal regulations surrounding the promotion and sale of compounded drugs, stating that they provided misleading marketing information which endangered patient safety. In line with this news, Hims shares experienced a dramatic decline, plummeting by 34.6% or $22.24, concluding the day at a mere $41.98 per share. This stock price dip underlines the substantial financial damage inflicted on affected investors who invested based on the implied promises of the company.

Faruqi & Faruqi emphasizes the importance of securing the most competent legislative representation for all investors adversely impacted by these occurrences. They stress that any member of the affected group may either seek to lead the case or remain a class member, assuring that their chances to recover any losses will not be affected by their decision to take a proactive approach. Moreover, the firm is keen on soliciting information tied to Hims' actions from whistleblowers, former employees, and shareholders to bolster their investigation outcome.

For those interested in learning more about the class action case against Hims & Hers Health, access resources on the Faruqi & Faruqi website or directly reach out to securities litigation partner Josh Wilson via the provided contact details. In the realm of securities litigation, the firm has established a reputation since its inception in 1995 — recovering hundreds of millions for investors nationwide.

Faruqi & Faruqi continues to navigate the complex landscape of securities law with a keen focus on safeguarding investor interests and holding entities accountable for misrepresentation and fraudulent practices. As they proceed with the investigation, updates are readily available through their social media platforms and official communications.

Conclusion

In summary, the unfolding circumstances surrounding Hims & Hers Health provide a cautionary tale for investors, underscoring the critical nature of transparency and accountability in the corporate sector. Stakeholders are encouraged to stay informed and proactive while navigating their options in light of such significant legal developments.